Introduction:

Diabetes mellitus and hyperglycemia, in patients with COVID-19, predispose to greater severity of the disease and worse short-term outcomes.

Objective:

To identify clinical differences, of humoral parameters, evolution and in the use of medications in patients infected with SARS-CoV-2; in relation to glycemic status, during the COVID-19 pandemic.

Methods:

Retrospective study of all patients infected with SARS-CoV-2, treated at the Hospital Militar Dr. Mario Muñoz Monroy _until June/2020. Demographic variables, evolution of symptoms, hospital stay, personal pathological history, humoral parameters on admission, complications and use of medications were collected. Three groups were created: diabetic (n = 16), hyperglycemic (fasting blood glucose ≥ 7.8 mmol/L; n = 10) and normo glycemic (n = 219). Chi-square and Kruskal-Wallis H test were used for comparisons between groups. A 95% confidence interval was used.

Results:

Diabetic and hyperglycemic patients had a higher proportion of symptoms on admission, arterial hypertension, ischemic heart disease, chronic renal insufficiency, other antecedents, complications, mortality, and use of steroids and Jusvinza. In addition, they had lower values of hematocrit and lymphocytes, and higher values of neutrophils, platelets, creatinine, aspartate amino transferase, glutamyl transpeptidase, alkaline phosphatase and lactic dehydrogenase.

Conclusions:

Both diabetes and hyperglycemia predisposed to more severe clinical forms of COVID-19, with worse humoral parameters, evolution and higher mortality. Steroids and Jusvinza were used more frequently in these patients.

        · |     · |     · ( pdf )